IMU Biosciences and Waters partner on AI immune profiling platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
June 24, 2026 8:00 AM EDTIMUs AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time.Waters Biosciences technologies, including BD FACSDiscover and BD Rhapsody Instruments, will be used with IMUs AI analytics in research to deliver deeper, population-level disease insights.Partnership supports IMUs expansion of its world-leading immune dataset through large-scale studies, establishing a new standard for immune profiling.
LONDON--(BUSINESS WIRE)-- IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand,... More
